5 assets in Fallopian Tube Adenocarcinoma

Therapeutic assets addressing Fallopian Tube Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Fallopian Tube Adenocarcinoma	CanariaBio Inc.	P3	B (60)
Ipilimumab Fallopian Tube Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Fallopian Tube Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Oregovamab Fallopian Tube Adenocarcinoma	CanariaBio Inc.	P3	CCC (51)
Tolinapant Fallopian Tube Adenocarcinoma	National Cancer Institute (NCI)	P1/2	NR ()